Data/hora: 02/06/2024 12:07:49

Provedor de dados: | 55
País: | Brazil
Título: | Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma
Autores: | Petrilli,Antonio Sérgio; Cypriano,Monica; Dantas,Lenice Silva; Lee,Lúcia Martino; Luisi,Maria Flávio Augusto Vercillo; Silva,Katia Veronica Torres B.; Pereira,Carlos Alberto Pires.
Data: | 2003-04-01
Ano: | 2003
Palavras-chave: | Fever; Neutropenia; Leukemia; Lymphoma; Ticarcillin; Ceftriaxone.
Resumo: | BACKGROUND: The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative. METHODS: We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). RESULTS: Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm³ (T) and 201cells/mm³ (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71% of the episodes in the T group and 81% in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T group and three episodes (4%) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and 93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this study. CONCLUSION: In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections.
Tipo: | Info:eu-repo/semantics/article
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000200003
Editor: | Brazilian Society of Infectious Diseases
Relação: | 10.1590/S1413-86702003000200003
Formato: | text/html
Fonte: | Brazilian Journal of Infectious Diseases  v.7 n.2 2003
Fonte: | info:eu-repo/semantics/openAccess